Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | DRD2 | P14416 | 11/20 | 0.57 |
| ▸ | HTR1A | P08908 | 10/20 | 0.57 |
| ▸ | DRD3 | P35462 | 9/20 | 0.57 |
| ▸ | HTR2A | P28223 | 9/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.57 |
| ▸ | DRD1 | P21728 | 3/20 | 0.57 |
| ▸ | DRD5 | P21918 | 3/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5178761 | 0.89 | DRD2 (0.65) | MAPTDRD2HTR1ADRD3HTR2A | |
| SCHEMBL8011318 | 0.85 | DRD2 (0.69) | DRD2HTR1ADRD3HTR2ATMEM97 | |
| SCHEMBL8102656 | 0.83 | KDM4E (0.63) | MAPTDRD2HTR1ADRD3HTR2A | |
| SCHEMBL16218814 | 0.83 | MAPT (0.56) | MAPTDRD2HTR1ADRD3HTR2A | |
| SCHEMBL5915112 | 0.81 | DRD2 (0.68) | MAPTDRD2HTR1ADRD3HTR2A | |
| SCHEMBL2091554 | 0.81 | HTR1A (0.56) | MAPTDRD2HTR1ADRD3HTR2A | |
| SCHEMBL7739933 | 0.81 | MAPT (0.61) | MAPTDRD2HTR1ASIGMAR1GAA | |
| SCHEMBL1307372 | 0.81 | MAPT (0.58) | MAPTDRD2HTR1ADRD3HTR2A | |
| SCHEMBL10365486 | 0.81 | HTR1A (0.57) | MAPTDRD2HTR1ADRD3HTR2A | |
| SCHEMBL5836202 | 0.81 | KCNH2 (0.69) | DRD2HTR1ADRD3HTR2ATMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1186318-C | Novel benzene amine compound, its prepn. process and medicinal compsns. contg. them | SAVOIER LAB (FR) | 2005-01-26 | — | — | CN | disclosed |
| EP-1275641-B1 | Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-01-12 | — | — | EP | disclosed |
| US-6713634-B2 | SEROTONIN RECEPTOR ANTAGONIST | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| US-6664251-B2 | Serotonin receptor antagonist; treating cardiovascular disorder | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| US-20030166926-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-0686632-B1 | BENZOTHIAZINE DERIVATIVE | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-20030078256-A1 | Benzothiazine derivative | SUNTORY LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6541471-B1 | Useful as a TXA2 receptor antagonist and a 5-HT2 receptor antagonist | LES LABORATOIRES SERVIER (FR) | 2003-04-01 | — | — | US | disclosed |
| CN-1397547-A | Novel benzene amine compound, its prepn. process and medicinal compsns. contg. them | SAVOIER LAB (FR) | 2003-02-19 | — | — | CN | disclosed |
| EP-1275641-A2 | Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-01-15 | — | — | EP | disclosed |
| CN-1058492-C | benzothiazine derivatives | SUNTORY LTD (JP) | 2000-11-15 | — | — | CN | disclosed |
| US-6100265-A | BENZOTHIOPYRAN AND THIENOTHIOPYRAN DERIVATIVES; SEROTONIN-2 BLOCKING ACTION; TREATMENT OF CIRCULATORY DISEASES IN GENERAL SUCH AS HYPERTENSION, ISCHEMIC HEART DISEASE, CEREBROVASCULAR DISTURBANCE, AND PERIPHERAL CIRCULATORY DISTURBANCE | SUNTORY LIMITED (JP) | 2000-08-08 | — | — | US | disclosed |
| US-6001827-A | Benzothiazine derivative | SUNTORY LIMITED (JP) | 1999-12-14 | — | — | US | disclosed |
| US-5977111-A | Thiopyran derivatives | SUNTORY LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5962448-A | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5874429-A | ANTIISCHEMIC AGENTS; CEREBROVASCULAR DISORDERS; CIRCULATORY IDSORDERS | SUNTORY LIMITED (JP) | 1999-02-23 | — | — | US | disclosed |
| EP-0807632-A1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LIMITED (JP) | 1997-11-19 | — | — | EP | disclosed |
| EP-0749971-A1 | Thiopyran derivatives | SUNTORY LIMITED (JP) | 1996-12-27 | — | — | EP | disclosed |
| CN-1119859-A | benzothiazine derivatives | SUNTORY LTD (JP) | 1996-04-03 | — | — | CN | disclosed |
| EP-0686632-A1 | BENZOTHIAZINE DERIVATIVE | SUNTORY LIMITED (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166926-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | MAPT 2226/4885DRD2 34/4885HTR1A 7/4885 |
| US-20030078256-A1 | Benzothiazine derivative | TPH2, ADRB2, TPH1 | MAPT 4423/4885DRD2 402/4885HTR1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.